Abstract: This study investigates the development and evaluation of rosuvastatin-loaded polymeric nanoparticles as a targeted wound-healing therapy. By integrating rosuvastatin into nanocarriers, the work aims to overcome solubility and bioavailability limitations and to enhance therapeutic outcomes in cutaneous wound repair. Six nanoparticle formulations were prepared via the nanoprecipitation method, varying polymer type and excipient content. Particle size, polydispersity index and zeta potential were measured by dynamic light scattering, while drug-loading efficiency was determined spectrophotometrically. In vitro release study was assessed. The optimized formulation was incorporated into a Carbopol 940 gel and evaluated in a rat excisional wound model, with comparisons against an untreated control, a commercial drug-based dressing and blank hydrogel. Wound-area reduction and healing percentages were quantified over 14 days. The PVP-K90–based formulation exhibited the smallest mean diameter, narrow size distribution and high entrapment efficiency. In vitro, this system achieved higher cumulative rosuvastatin release at 24 h. In vivo, the rosuvastatin hydrogel accelerated the wound-healing cascade, achieving complete closure by day 14, with significantly greater re-epithelialization and neovascularization compared to controls (p < 0.001). The findings demonstrate that polymeric nanoprecipitation offers a versatile platform to tailor nanoparticle characteristics and release profiles, translating into marked improvements in wound repair. This approach holds promise for the clinical translation of statin-based nano formulations in both acute and chronic wound management.
Processing Request
No Comments.